Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.31 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075000 | 1.00 | F10 (0.35) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7082247 | 0.84 | MAPK13 (0.42) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7082583 | 0.84 | RAPGEF4 (0.35) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7081925 | 0.81 | MAPK14 (0.44) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7081924 | 0.81 | MAPK14 (0.44) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7076728 | 0.79 | MAPK13 (0.45) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7076724 | 0.79 | MAPK13 (0.45) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7081240 | 0.79 | MAPK13 (0.39) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7081237 | 0.79 | MAPK13 (0.39) | F10GAAMAPTALDH1A1AGTR1 | |
| SCHEMBL7074441 | 0.79 | MAPK14 (0.54) | F10ALDH1A1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | claimed |
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | MAPKAPK2, MAP3K2, MAP3K1 | F10 3854/4885GAA 3825/4885MAPT 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.